Skip to main content

Table 1 MICs of wild-type K. aerogenes KE-Y1 and its transposon insertion mutants (KE-Y3 and KE-Y6), its complemented derivatives, and the ampG knockout mutant (KE-Y1ΔampG)

From: Role of AmpG in the resistance to β-lactam agents, including cephalosporins and carbapenems: candidate for a novel antimicrobial target

Antibiotics

KE-Y1 Wild-type

KE-Y3 Transposon mutant

KE-Y3 + pADY123::ampG

KE-Y6 Transposon mutant

KEY6 + pADY123::ampG

KE- Y1ΔampG

Ampicillin

 ≥ 32(R)

 ≥ 32(R)

 ≥ 32(R)

 ≤ 2*(R*)

 ≥ 32(R)

 ≤ 4(S)

SAM

 ≥ 32(R)

 ≤ 2(R*)

 ≥ 32(R)

 ≤ 2(R*)

 ≥ 32(R)

 ≤ 2(S)

TZP

 ≥ 128(R)

 ≤ 4(S)

 ≥ 128(R)

 ≤ 4(S)

 ≥ 128(R)

 ≤ 4(S)

Cefazolin

 ≥ 64(R)

32(R)

 ≥ 64(R)

16 (R*)

 ≥ 64(R)

32(R)

Cefoxitin

 ≥ 64(R)

 ≥ 64(R)

 ≥ 64(R)

 ≥ 64(R)

 ≥ 64(R)

 ≥ 64(R)

Cefotaxime

 ≥ 64(R)

 ≤ 1(S)

 ≥ 64(R)

 ≤ 1(S)

 ≥ 64(R)

 ≤ 1(S)

Ceftazidime

 ≥ 64(R)

 ≤ 1(S)

32(R)

 ≤ 1(S)

 ≥ 64(R)

 ≤ 1(S)

Cefepime

 ≤ 1(S)

 ≤ 1(S)

 ≤ 1(S)

 ≤ 1(S)

2(S)

 ≤ 1(S)

Aztreonam

 ≥ 64(R)

 ≤ 1(S)

32(R)

 ≤ 1(S)

 ≥ 64(R)

 ≤ 1(S)

Ertapenem

 ≥ 8(R)

 ≤ 0.5(S)

 ≥ 8(R)

 ≤ 0.5(S)

 ≥ 8(R)

 ≤ 0.5(S)

Meropenem

8(R)

 ≤ 0.25(S)

2(I)

 ≤ 0.25(S)

4(R)

 ≤ 0.25(S)

Amikacin

 ≤ 2(S)

 ≤ 2(S)

 ≤ 2(S)

 ≤ 2(S)

 ≤ 2(S)

 ≤ 2(S)

Gentamicin

 ≤ 1(S)

 ≥ 16(R)

 ≥ 16(R)

 ≥ 16(R)

 ≥ 16(R)

 ≤ 1(S)

Levofloxacin

 ≤ 0.12(S)

 ≤ 0.12(S)

 ≤ 0.12(S)

 ≤ 0.12(S)

 ≤ 0.12(S)

 ≤ 0.12(S)

Tigecycline

1(S)

 ≤ 0.5(S)

 ≤ 0.5(S)

 ≤ 0.5(S)

 ≤ 0.5(S)

 ≤ 0.5(S)

TMP/SMX

 ≤ 20(S)

 ≤ 20(S)

 ≤ 20(S)

 ≤ 20(S)

 ≤ 20(S)

 ≤ 20(S)

  1. *: AES modified (Advanced Expert system)